Despite posting strong results in the final quarter of 2025, MSD (Merck & Co) has cut its 2026 guidance more than analysts ...

SanegeneBio has entered into a $1.5bn global licensing agreement with Genentech, part of the Roche Group, for one of its RNAi ...

As FY25 results reveal a mixed year for Pfizer, the company is looking to turn its fortunes around with newly acquired Metsera obesity assets.

Aquestive has received a CRL from the FDA regarding its NDA for Anaphylm, which aims to treat type I allergic reactions in patients weighing 30kg or more.

Historically a steel production hub, Lehigh Valley will now help manufacture Lilly’s weight loss drug hopeful retatrutide.

Kyowa Kirin will now file for rocatinlimab’s US approval in atopic dermatitis (AD), which was once Amgen’s most late-stage pipeline candidate.

The California Institute for Regenerative Medicine has approved the RAPID funding programme, setting aside $100m over two ...

Repertoire Immune Medicines has collaborated with Eli Lilly for the development of tolerising therapies to treat several ...

The two companies reportedly could not agree on a price, leaving pharma’s first potential megadeal of 2026 on ice.

This year, sales of Eliquis (apixaban) are projected to decline by 15.2% due to the loss of its European market exclusivity ...